Biomea Fusion, Inc. cotiza a 1.36 USD y tiene una capitalización bursátil de $98M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.17 | $-0.17 | $-0.12 |
| Estimado | $-0.22 | $-0.23 | $-0.19 | $-0.22 |
| Sorpresa | — | +26.1% | +10.5% | +45.5% |
| Métrica | BMEA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -209.1% | -40.4% | -168.7% |
| ROA | -105.5% | -32.0% | -73.5% |
| Current Ratio | 5.23 | 2.84 | +2.39 |
| Debt / Equity | — | 0.28 | — |